Lauren Fane

Ms. Lauren Fane

Case Western Reserve University, Cleveland, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Lauren FaneLauren Fane
Lauren Fane
Tithi BiswasTithi Biswas
Tithi Biswas
CJCharulata Jindal
Charulata Jindal
YCYuk Ming Choi
Yuk Ming Choi
Jimmy Thomas EfirdJimmy Thomas Efird
Jimmy Thomas Efird
Asian (AZN) women are a heterogeneous group, comprising a wide array of cultural beliefs, languages, and healthcare needs. Yet, studies of breast cancer (BCa) risks and outcomes predominately consider AZNs in aggregate, assuming that the distinct ethnicities have similar disease profiles and homogeneous responses to treatment. This stereotypical portrayal of AZNs as a homogenous group tends to mask disparities. For example, healthcare-seeking behaviors and attitudes of medical providers toward AZN BCa patients frequently differ within this group and from other races. Misconceptions may arise that significantly influence the prevention, detection, treatment, and post-therapeutic care of AZN women. In addition to low BCa screening rates among AZN women, disparities also exist in various stages of BCa treatment—omission of radiation after breast-conserving surgery, less access to hypofractionation, underutilization of hormonal therapy, and higher-cost treatment owing to high HER2+ incidence. In this perspective, we highlight the need for disaggregated research of BCa among AZN women and advocate for comprehensive, culturally sensitive strategies to address health disparities in this priority population. Improving BCa literacy and awareness, access to care, and equitable recruitment into clinical trials are a few amelioratory goals to consider in the future.

20 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Lauren FaneLauren Fane
Lauren Fane
Jimmy Thomas EfirdJimmy Thomas Efird
Jimmy Thomas Efird
CJCharulata Jindal
Charulata Jindal
Tithi BiswasTithi Biswas
Tithi Biswas
The most common immune-related adverse events (irAEs) involve the skin, and several serve as predictors of response to immune checkpoint inhibitor (ICI) therapy, especially in melanoma. Patients with pre-existing skin autoimmune diseases (ADs) have been excluded from ICI studies for safety concerns, yet recent research has shown that dermatological ADs can be managed without discontinuing ICI therapy. Patients with ADs respond as well or better to ICIs and can be included as candidates in clinical trials. Frequently taken during ICI therapy, steroids impair immunotherapy efficacy in certain anatomical sites of tumors but not others, including the brain. ICI efficacy can be enhanced by radiotherapy without increasing adverse events, as neoadjuvant radiotherapy is thought to sensitize tumors to ICIs. This perspective highlights clinical autoimmune considerations of ICI therapy in melanoma and discusses important areas for future exploration.

11 April 2023 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
Lauren FaneLauren Fane
Lauren Fane
AWAngela H. Wei
Angela H. Wei
RTRaghav Tripathi
Raghav Tripathi
JBJeremy S. Bordeaux
Jeremy S. Bordeaux

24 December 2023 in Journal of the American College of Radiology
Verified
Journal Article
Closed access
Lauren FaneLauren Fane
Lauren Fane
DJDavid W. Jordan
David W. Jordan